Clinical manifestations of respiratory lesions in COVID 19

The new coronavirus disease pandemic of 2019 (COVID-19) is seriously testing health systems and economies around the world and is rightfully considered the main health emergency in a century. A significant proportion of patients develop pneumonia, requiring hospitalization or progression to the manifestation of respiratory complications. In this article, we compared some laboratory data on community-acquired pneumonia of bacterial origin with COVID-19 associated pneumonia. A retrospective analysis of 60 case histories with a preliminary diagnosis of community-acquired pneumonia was carried out. After analyzing the gender-anamnestic, clinical, instrumental and laboratory characteristics of COVID-19 associated pneumonia, we came to the conclusion that the clinical picture was represented by chills, unproductive cough, pain and a feeling of congestion in the chest when breathing, shortness of breath, anosmia. In the UAC, a normal level of leukocytes or a slight leukopenia was determined, in contrast to bacterial infection. The level of ESR is exceeded by 1.8 times. LDH and CRP are exceeded by 3.0 and 2.8 times, respectively, in contrast to bacterial community-acquired pneumonia. Procalcitonin in community-acquired pneumonia of bacterial origin was elevated (≥ 0.5 ng/ml), procalcitonin was not detected in COVID-19 associated pneumonia.